The following is a summary of “Time-dependent recovery of renal impairment in patients with newly diagnosed multiple myeloma, ...

Black Americans have double the risk of developing multiple myeloma compared to white Americans and are diagnosed at younger ...

For patients with newly diagnosed multiple myeloma (NDMM) receiving dexamethasone induction, dose reductions do not ...

Traditionally carrying a dire prognosis, the treatment paradigm for multiple myeloma is changing, with CAR T therapies, ...

New cell therapy, Cilta-cel, shows promise in the treatment of multiple myeloma, providing a personalised approach with the ...

Study finds low peripheral blood lymphocyte count at diagnosis predicts worse overall survival in multiple myeloma patients.

The company previously teased the overall survival (OS ... of relapsed or refractory multiple myeloma." The data reported at ASH revealed a 74% OS rate in the Blenrep plus BorDex (BVd) arm ...

Thalidomide was the first immunomodulatory agent approved for use in myeloma. Although highly ... Overall response rate; OS: Overall survival; PFS: Progression-free survival; PR: Partial response ...

Opens in a new tab or window A novel combination for relapsed/refractory multiple ... rates in subgroups of interest included seven of eight patients with International Staging System III myeloma ...

Primary results of phase 3 AURIGA study indicated that dual maintenance therapy after transplant led to improved outcomes.

The panelist discusses how real-world evidence for CAR T in relapsed/refractory multiple myeloma shows promising efficacy but ...